QTI vs TCRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits critical financial weakness with a Piotroski F-Score of 1/9, indicating severe fundamental distress. Despite an extraordinary YoY revenue growth of 877.20%, the company remains deeply unprofitable with a profit margin of -111.40% and a history of massive earnings misses. Technical trends are overwhelmingly bearish, characterized by a 78.7% price collapse over the last six months. While short-term liquidity is stable, the combination of poor health scores and negative earnings progression suggests a high risk of further devaluation.
TCRX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe financial distress across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 8.41, this is offset by a catastrophic operating margin of -851.50% and a 5-year price decline of 86.4%. The stock is currently a speculative binary play, where a massive disconnect exists between the fundamental health (extremely poor) and analyst price targets ($6.00).
Compare Another Pair
Related Comparisons
QTI vs TCRX: Head-to-Head Comparison
This page compares QT Imaging Holdings, Inc. (QTI) and TScan Therapeutics, Inc. (TCRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.